

Biologic effects of mindfulness meditation: growing insights into neurobiologic aspects of the prevention of depression

Simon N. Young, PhD

Coeditor-in-Chief, *Journal of Psychiatry and Neuroscience*, and the Department of Psychiatry, McGill University, Montréal, Que.

A recent paper in the *Archives of General Psychiatry* confirms that mindfulness-based cognitive therapy (MBCT) “offers protection against relapse/recurrence on a par with that of maintenance antidepressant pharmacotherapy.”¹ It is a tribute to the accumulated wisdom of humankind that a traditional Buddhist meditation practice going back 2500 years, which was originally designed in part to deal with the problem of human suffering, has been successfully adapted to prevent the relapse of depression in the modern era. Buddhist meditation techniques were originally adapted by Jon Kabat-Zinn, founding executive director of the Center for Mindfulness in Medicine, Health Care, and Society at the University of Massachusetts Medical School (www.umassmed.edu/Content.aspx?id=43102), for mindfulness-based stress reduction (MBSR). Reviews of MBSR studies suggest that it decreases depression, anxiety and psychological distress in people with chronic somatic diseases² and that it reduces stress, ruminative thinking and trait anxiety in healthy people.³ Mindfulness-based cognitive therapy is similar to MBSR and is designed to change some of the cognitions that are associated with depression.⁴

Mindfulness has been described as “paying attention in a particular way: on purpose, in the present moment, and non-judgementally.”⁵ In contrast to traditional cognitive behavioural therapy in which dysfunctional thoughts are targeted, the objective of MBCT is to help individuals learn, at times, to become aware of thoughts, feelings and bodily sensations rather than trying to modify them or acting on them. A core skill learned in MBCT is how to recognize and disengage from self-perpetuating patterns of ruminative, negative thought through sustained attention and attention-switching exercises. This self-regulation of attention is thought to help recovered depressed individuals shift attention away from the rumination about dysfunctional cognitions, which may be reactivated during transient mood lowering, and thus allows them to process depression-related information differ-

ently.⁴ Dysfunctional cognitions, such as “If I do not do as well as other people in a particular task it means I am inferior,” “My value as a person depends on what others think of me,” or “It is important that everyone likes me,”⁶ are risk factors for depression in adults⁷⁻⁹ and children.^{10,11} Mindfulness-based cognitive therapy targets the ruminative thinking by enhancing awareness and monitoring of thoughts. This suggests that MBCT might not only decrease relapse in depression but also prevent the onset of the first episode of depression in susceptible people. As Insel and Scolnick¹² have pointed out, “the great public health success stories of the past century are largely stories of prevention.” Insights into both psychologic and biologic factors that are associated with the prevention of depression should help in the long run to develop better strategies for prevention. I describe some of the biologic factors associated with dysfunctional cognitions and what is known about the biologic effects of MBCT. Finally, I suggest some possible research directions that may provide more information on the systems that MBCT influences when preventing the onset of depression.

Different forms of meditation have been compared with various control interventions, some of which did not have similar intensity. As a result, the exact component of meditation that produces a beneficial effect is not clear, although the targeting of dysfunctional cognitions is probably the most plausible mechanism. In the rest of this editorial, different forms of meditation are assumed to have similar effects.

The idea that serotonin is related to the control of mood persists, and a small portion of the literature relates serotonin function to dysfunctional attitudes. In one of the first studies of this type, dysfunctional attitudes decreased in healthy participants when they were treated with the serotonin-releasing drug fenfluramine.¹³ In depressed patients, one of the more common abnormalities reported using positron emission tomography (PET) is an increase in serotonin 2A (5-HT_{2A}) binding potential. In depressed patients, high 5-HT_{2A} binding

Correspondence to: Dr. S.N. Young, Department of Psychiatry, McGill University, 1033 Pine Ave. W, Montréal QC H3A 1A1; Simon.Young@mcgill.ca

J Psychiatry Neurosci 2011;36(2):75-7.

DOI: 10.1503/jpn.110010

potential in the cortex was positively associated with dysfunctional attitudes, and the mean value was higher in those exhibiting extremely dysfunctional attitudes than in controls.¹³ In recovered depressed patients, there was also a positive correlation between 5-HT_{2A} binding potential and dysfunctional attitudes.¹⁴ No difference in regional serotonin transporter binding potential was found between participants with major depression and healthy participants. However, in brain regions containing mainly serotonergic nerve terminals, the binding potential was significantly higher in depressed patients with highly negativistic dysfunctional attitudes. There was also a strong association between the serotonin transporter binding potential and dysfunctional attitudes in depressed patients.¹⁵ Treatment of depressed patients with fluoxetine decreases dysfunctional attitudes.¹⁶ Finally, the mood lowering of recovered depressed patients on medications in response to acute tryptophan depletion was related to their cognitive reactivity,¹⁷ a measure of the extent to which dysfunctional attitudes appear when mood is low.

The biologic factors associated with mindfulness meditation have been studied using a variety of different methods. As discussed in recent reviews,^{18,19} changes in brain function during meditation have been documented using electrophysiology, single photon emission computed tomography, PET and functional magnetic resonance imaging. Results differ somewhat, possibly owing to the use of different forms of meditation, but in general show increased signals in brain regions related to affect regulation and attentional control, with increased release of dopamine. Long-term brain changes are of greater interest to MBCT as a preventive strategy. Several studies have compared brain morphology of experienced meditators with matched controls, and findings include increased cortical thickness along with reduced age-related cortical thinning.¹⁸ However, these results could be owing to pre-existing differences in those who choose to meditate and those who do not choose to do so. Two recent studies have overcome this problem by looking at brain morphology before and after an 8-week meditation program. The first study found increases in grey matter in the left hippocampus, the posterior cingulate cortex, the temporo-parietal junction and the cerebellum in those who did MBSR relative to wait-list controls.²⁰ The second study looked at MBSR in stressed but otherwise healthy individuals. Reductions in stress correlated positively with decreases in right basolateral amygdala grey matter density.²¹

Changes in the brain owing to mindfulness meditation could be a direct effect on the brain or could be mediated in whole or in part by an indirect mechanism. Reduced stress could decrease glucocorticoid levels and modulate the immune system (e.g., cytokines), both of which could feed back to alter the brain. A recent review concluded that there is accumulating evidence that plasma and salivary cortisol can be reduced by MBSR.²² Several studies have looked at immune parameters. In patients with cancer, MBSR tended to return cytokine levels and natural killer cell activities toward normal levels.^{23,24} In healthy people, meditation increased the antibody titer to influenza vaccine,²⁵ lowered the stress-induced increase in interleukin-6²⁶ and decreased C-reactive protein.²⁷

Research on the biologic effects of meditation is relatively new, and there is scope for more work. For example, no studies have yet looked at the effect of meditation on serotonin function. Mindfulness-based cognitive therapy is designed in part to decrease dysfunctional attitudes, which are related to 5-HT_{2A} binding potential. Would MBCT alter 5-HT_{2A} receptor function? As mentioned, in recovered depressed patients on medication, the lowering of mood after acute tryptophan depletion was related to their cognitive reactivity (the extent to which they developed dysfunctional attitudes when their mood was lowered).¹⁷ If MBCT decreases dysfunctional attitudes, would it also decrease the lowering of mood in response to acute tryptophan depletion?

If MBCT is to be tested for the prevention of the onset of the first episode of depression, and not just relapse, knowledge about how it works will be helpful in selecting participants for such a study. Prevention studies usually last years and involve a large number of participants; they are therefore very expensive. Unfortunately, medicine provides many examples of negative prevention trials. For example, a large trial of β carotene and vitamin A found no benefit after 4 years of treatment and an adverse effect on the incidence of lung cancer and cardiovascular disease in smokers,²⁸ whereas a study lasting 8 years found no beneficial effect of a low-fat diet on coronary heart disease.²⁹ A prevention study with MBCT would not be easy to carry out. The success of such a study might be influenced by how the patients were selected. Participants should have a strong motivation to practise meditation for years and a high risk for depression. People who have never experienced depression but come from a family with a high incidence of depression have a high risk for the illness and, having seen the effects of depression on their family members, would have a good motivation to practise MBCT if there were a chance that it would protect them from the illness. In addition, if they had above-average levels of dysfunctional cognitions and cognitive reactivity, they might be expected to benefit from MBCT. The biologic measures that might be useful to help select patients must be speculative at this stage, but 1 or more serotonergic measures might be candidates. For a prevention study with a large sample size, simple measures would be important. Platelet serotonin can be measured relatively easily, and in one study, people with high trait anxiety had more dysfunctional attitudes and high platelet serotonin levels than controls with low trait anxiety.³⁰ Furthermore, platelet 5-HT_{2A} receptor binding was positively related to suicidal ideation in depressed patients,³¹ so the idea that a simple biologic marker for response to MBCT might be discovered is plausible. Increasing knowledge about the neurobiologic effects of MBCT may foster the convergence of the biologic and psychological aspects of psychiatry and also aid in the design of much needed primary prevention studies in mood disorders.

Competing interests: None declared.

References

1. Segal ZV, Bieling P, Young T, et al. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive

- therapy, or placebo, for relapse prophylaxis in recurrent depression. *Arch Gen Psychiatry* 2010;67:1256-64.
2. Bohlmeijer E, Prenger R, Taal E, et al. The effects of mindfulness-based stress reduction therapy on mental health of adults with a chronic medical disease: a meta-analysis. *J Psychosom Res* 2010; 68:539-44.
 3. Chiesa A, Serretti A. Mindfulness-based stress reduction for stress management in healthy people: a review and meta-analysis. *J Altern Complement Med* 2009;15:593-600.
 4. Segal ZV, Williams JMG, Teasdale JD. *Mindfulness-based cognitive therapy for depression — a new approach to preventing relapse*. New York (NY): Guilford Press; 2002.
 5. Kabat-Zinn J. *Wherever you go, there you are: mindfulness meditation in everyday life*. New York (NY): Hyperion; 1994.
 6. de Graaf LE, Roelofs J, Huibers MJ. Measuring dysfunctional attitudes in the general population: the dysfunctional attitude scale (form A) revised. *Cognit Ther Res* 2009;33:345-55.
 7. Church NF, Brechman-Toussaint ML, Hine DW. Do dysfunctional cognitions mediate the relationship between risk factors and post-natal depression symptomatology? *J Affect Disord* 2005;87:65-72.
 8. Segal ZV, Pearson JL, Thase ME. Challenges in preventing relapse in major depression: report of a National Institute of Mental Health Workshop on state of the science of relapse prevention in major depression. *J Affect Disord* 2003;77:97-108.
 9. Teasdale JD, Cox SG. Dysphoria: self-devaluative and affective components in recovered depressed patients and never depressed controls. *Psychol Med* 2001;31:1311-6.
 10. Abela JRZ, Brozina K, Haigh EP. An examination of the response styles theory of depression in third- and seventh-grade children: a short-term longitudinal study. *J Abnorm Child Psychol* 2002;30: 515-27.
 11. Abela JRZ, Skitch SA. Dysfunctional attitudes, self-esteem, and hassles: cognitive vulnerability to depression in children of affectively ill parents. *Behav Res Ther* 2007;45:1127-40.
 12. Insel TR, Scolnick EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. *Mol Psychiatry* 2006;11:11-7.
 13. Meyer JH, McMain S, Kennedy SH, et al. Dysfunctional attitudes and 5-HT₂ receptors during depression and self-harm. *Am J Psychiatry* 2003;160:90-9.
 14. Bhagwagar Z, Hinz R, Taylor M, et al. Increased 5-HT_{2A} receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [11C]MDL 100,907. *Am J Psychiatry* 2006;163:1580-7.
 15. Meyer JH, Houle S, Sagrati S, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. *Arch Gen Psychiatry* 2004;61:1271-9.
 16. Fava M, Bless E, Otto MW, et al. Dysfunctional attitudes in major depression: changes with pharmacotherapy. *J Nerv Ment Dis* 1994; 182:45-9.
 17. Booij L, van der Does AJW. Cognitive and serotonergic vulnerability to depression: convergent findings. *J Abnorm Psychol* 2007;116:86-94.
 18. Rubia K. The neurobiology of meditation and its clinical effectiveness in psychiatric disorders. *Biol Psychol* 2009;82:1-11.
 19. Chiesa A, Serretti A. A systematic review of neurobiological and clinical features of mindfulness meditations. *Psychol Med* 2010;40: 1239-52.
 20. Hölzel BK, Carmody J, Vangel M, et al. Mindfulness practice leads to increases in regional brain gray matter density. *Psychiatry Res* 2011;191:36-43.
 21. Hölzel BK, Carmody J, Evans KC, et al. Stress reduction correlates with structural changes in the amygdala. *Soc Cogn Affect Neurosci* 2010;5:11-7.
 22. Matousek RH, Dobkin PL, Pruessner J. Cortisol as a marker for improvement in mindfulness-based stress reduction. *Complement Ther Clin Pract* 2010;16:13-9.
 23. Witek-Janusek L, Albuquerque K, Chroniak KR, et al. Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. *Brain Behav Immun* 2008;22:969-81.
 24. Carlson LE, Speca M, Patel KD, et al. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. *Psychosom Med* 2003;65:571-81.
 25. Davidson RJ, Kabat-Zinn J, Schumacher J, et al. Alterations in brain and immune function produced by mindfulness meditation. *Psychosom Med* 2003;65:564-70.
 26. Pace TW, Negi LT, Adame DD, et al. Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress. *Psychoneuroendocrinology* 2009;34:87-98.
 27. Fang CY, Reibel DK, Longacre ML, et al. Enhanced psychosocial well-being following participation in a mindfulness-based stress reduction program is associated with increased natural killer cell activity. *J Altern Complement Med* 2010;16:531-8.
 28. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med* 1996;334:1150-5.
 29. Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease: the women's health initiative randomized controlled dietary modification trial. *JAMA* 2006;295:655-66.
 30. Davis DD, Dunlop SR, Shea P, et al. Biological stress responses in high and low trait anxious students. *Biol Psychiatry* 1985;20:843-51.
 31. Lauterbach E, Brunner J, Hawellek B, et al. Platelet 5-HT_{2A} receptor binding and tryptophan availability in depression are not associated with recent history of suicide attempts but with personality traits characteristic for suicidal behavior. *J Affect Disord* 2006;91:57-62.

ZELDOX®

COVERED BY FORMULARY ACROSS CANADA††

† Except PEI

‡ ZELDOX is listed as a General Benefit on the Ontario Drug Benefit Formulary and by the New Brunswick Prescription Drug Formulary. ZELDOX is listed as a full benefit to both lists of the Quebec formulary. ZELDOX has been added to the Alberta Health and Wellness Drug Benefit List as a full benefit. ZELDOX is covered by the Saskatchewan Drug Plan & Extended Benefits. ZELDOX has been added to Part 1 of the Manitoba Drug Benefit and Interchangeability List. ZELDOX is listed as a Limited Coverage Drug pursuant to the BC Pharmacare Special Authority Program. ZELDOX is also covered by the Nova Scotia Pharmacare, and by the Newfoundland and Labrador Prescription Drug Program with Special Authorization. ZELDOX has been included as a limited use benefit on the Non-Insured Health Benefits (NIHB) Drug Benefit List.



Member
TM Pfizer Inc., used under license
ZELDOX® Pfizer Products Inc., Pfizer Canada Inc., licensee
© 2011 Pfizer Canada Inc., Kirkland, Quebec H9J 2M5



Working together for a healthier world™